Vir Biotechnology Stock News

Let us take a look at five biotech/drug companies, namely, MRNA, EDIT, VIR, EBS and AERI, which are due to release their quarterly results on Feb 24.

Universal Health Services' (UHS) fourth-quarter results are likely to reflect the benefits of improving patient volumes.

Viatris' (VTRS) Q4 earnings might have gained from the solid performance of Lipitor, Influvac, Viagra and EpiPen.

Avid Bioservices (CDMO) is set to provide updates on its CDMO business and other such developments when it reports earnings results for third quarter of fiscal 2022.

An update on the IPO of Bausch+Lomb and regular top-line and bottom-line numbers will grab investors' attention when BHC reports Q4 results.

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front, the Food and Drug A

Vir Biotechnology, Inc. (VIR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vir Biotechnology, Inc. (VIR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The "The Nasal Cannula Market - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028" report has been added to ResearchAndMarkets.com''s offering. The nasal cannula device is used to deliver oxygen to patients with respiratory diseases such as asthma, lung cancer, pneumonia, Chronic Obstructive Pulmonary Diseases (COPD), and pulmonary fibrosis. This device is made up of plastic or silicon material and has a tube-like structure with two prongs to connect nostrils for providing oxygen. These tubes are placed behind the ear to allow for better adjustment of the prongs. These nasal cannula tubes are available at a low cost, which drives the growth of the nasal cannula market. There are different types of nasal cannulas available in the market which are used for pre-mature infants, adults suffering from respiratory diseases, patients with lung cancer, or patients with respiratory failure due to COVID-19. Market Dynamics Market players are indulged in inorganic activities such as collaborations in order to increase research and development activities for the treatment of respiratory diseases.

Vir's prospects depend entirely on the SARS-COV2 virus and emerging variants, if any.

Vir: Expansion Of Covid-19 Antiviral Drug And Hepatitis B Pipeline Makes It An Attractive Bet

Are these on your list of best health care stocks to buy right now?

SAN FRANCISCO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2021, on Thursday, February 24, 2022.

SAN FRANCISCO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter a